Abstract

Objectives: Little evidence exists regarding the management of orbital meningioma causing vision loss in the setting of neurofibromatosis Type 2 (NF2). We review here our experience with patients at risk for blindness due to intra-orbital meningioma.Design/Setting/Participants/Main Outcome Measures: The charts of patients with NF2 presenting for evaluation of intra-orbital meningioma and vision impairment between 2008 and 2013 were retrospectively reviewed in accordance with institutional IRB policies. Patients with primarily extra-orbital tumors and minimal intra-orbital extension were excluded. Charts were analyzed for the presence and/or imaging progression of intra-orbital tumor, presence of other optic apparatus pathology, presence and/ or progression of vision impairment, and intervention performed (if any).Results: Seven patients with intra-orbital meningioma on MRI and bilateral vision loss and/or unilateral visual impairment due to tumor and contralateral blindness of any etiology were identified. Patients without salvageable vision in either eye were excluded (n = 3). Diagnosis of meningioma was obtained either by biopsy or based on imaging assessment.Conclusion: Conservative management of orbital tumors in NF2 may be preferred in asymptomatic patients but may not be acceptable in patients with progressive visual decline. Radiation is a reasonable option for meningiomas of the orbit and optic nerve sheath. Finally, although the benefit of cranial nerve decompression in NF2 for preservation of facial nerve and hearing has previously been established, the role of optic nerve decompression for preservation of vision in NF2 remains poorly defined.

Highlights

  • While the clinical hallmark of neurofibromatosis type 2 (NF2) is deafness due to bilateral vestibular schwannomas, visual compromise in NF2 patients is characteristic of the disease

  • The prevalence of meningiomas involving the orbit and optic nerve sheath is higher in NF2 patients than in the general population [1]

  • The management of the NF2 patient with bilateral visual compromise is complicated by the fact that these patients are destined to bilateral deafness and dependence on lip reading for communication

Read more

Summary

Introduction

While the clinical hallmark of neurofibromatosis type 2 (NF2) is deafness due to bilateral vestibular schwannomas, visual compromise in NF2 patients is characteristic of the disease. In addition to the pathognomonic development of bilateral vestibular schwannomas, patients with NF2 are prone to the development of other benign tumors of the central and peripheral nervous system, including. Vision Preservation in NF2 intracranial and spinal meningiomas, ependymoma, and central and peripheral schwannomas. Non-neoplastic manifestations of NF2 occur that may compromise patients’ vision. The association of NF2 with sub-lenticular cataracts has long been appreciated, other non-neoplastic ophthalmologic manifestations of NF2, such as orbital hamartoma [2] and epiretinal membranes occur more frequently than in the general population [3]. The management of the NF2 patient with bilateral visual compromise is complicated by the fact that these patients are destined to bilateral deafness and dependence on lip reading for communication

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call